Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
about
Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interactionDiversity of actions of GnRHs mediated by ligand-induced selective signalingEpidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasionPromotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways.Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist.Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.GnRH agonists induce endometrial epithelial cell apoptosis via GRP78 down-regulationCetrorelix in the treatment of female infertility and endometriosis.Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.Role of endocrine and growth factors on the ovarian surface epithelium.Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes.Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues.Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.Luteinizing hormone-releasing hormone antagonists.Receptor-mediated tumor targeting based on peptide hormones.The extrapituitary effects of GnRH antagonists and their potential clinical implications: a narrated review.Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and MetastasisNo supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro.Gonadotropin-releasing hormone analogues reduce the proliferation of endometrial stromal cells but not endometriotic cells.Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals.GnRH ActionMolecular co‐evolution of Gonadotropin‐releasing hormones and their receptors
P2860
Q28484928-11B36145-BA90-4C24-A5AC-064AF0DF6586Q30439870-230B2650-8E65-4C64-AC25-209F8E742676Q33642087-AB391A18-D510-49DE-AD19-D4AD37D30BE0Q33642178-AFDCEAA6-3E6C-4876-B2B0-0F9174B9C7A4Q33642701-149979A0-E49D-4FD7-AD0B-22B38BE4730CQ33754466-D1084608-BC21-4AC3-9904-031EFA50894DQ34173433-88DF06B0-067C-4988-BAA2-A344F28E2DF7Q34558581-369386A6-D32B-4175-989E-D70ED012A309Q34571550-A81629DD-CAA9-4953-81DB-E9EE4CDA9A50Q34644401-61EAFE4C-F95E-4571-AD01-8EB04F633C88Q36703049-5FC0AFF3-193C-4EDD-BB92-65110DD53623Q36970080-162F2B0A-07E3-446C-8200-6496373C6332Q37311388-6213A6CD-E89A-4894-8B16-1F2F7D56315FQ37311391-4C254A12-7A42-4FE7-9A0C-FEC081F5415BQ37331064-720AC380-FB1D-478F-BB5E-48F0CC3CFEAFQ37638747-7C129FC2-BF58-4EED-8988-0F78A41B9F69Q37641368-F80F4D93-A7C7-4855-99D6-BB2867AD74C5Q38046587-0B5E44C7-6A2B-4777-B9AB-DDF3C65857A9Q38756598-82CA9FE8-9125-49E6-A5C2-BB94BFE2D607Q38882916-E14658B4-8F44-4DD0-952D-1D92EF2B08EEQ40066199-A67757BF-807E-45AD-BE54-C4DE9E4CDBA0Q41242658-0942463E-B6B0-44EF-AE49-757C3DC20E0CQ41959762-EBE48E10-2A58-491F-A5A0-1E4FC1E4AD30Q45297110-8A678740-10AC-4C44-923E-A5721B072B80Q47221769-1691CB90-FE05-42E0-A733-6FB8B1CCB947Q57918892-16B85AF8-5D48-44D7-8E02-8AD21018D91AQ58185647-777ADB6E-850D-462B-8B54-DC4B688B527A
P2860
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antiproliferative effects of t ...... ough the GnRH type I receptor.
@en
type
label
Antiproliferative effects of t ...... ough the GnRH type I receptor.
@en
prefLabel
Antiproliferative effects of t ...... ough the GnRH type I receptor.
@en
P2093
P356
P1476
Antiproliferative effects of t ...... ough the GnRH type I receptor.
@en
P2093
Anika Horst
Britta Kairies
Carsten Gründker
Günter Emons
Lars Schlotawa
Nicola Eicke
Volker Viereck
P304
P356
10.1530/EJE.0.1510141
P577
2004-07-01T00:00:00Z